Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China;Department of Hepatology Division 2, Peking University Ditan Teaching Hospital, Beijing 100015, China.
Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Biomed Environ Sci. 2021 Jun 20;34(6):443-453. doi: 10.3967/bes2021.061.
To investigate the changes in the cytokine profiles of chronic hepatitis B (CHB) patients undergoing antiviral treatment.
Hepatitis B e antigen (HBeAg)-positive patients were treated with Pegylated interferon (PEG-IFN) and entecavir (ETV). Clinical biochemistry and cytokines were detected at baseline and every 3 months.
In all, 200 patients completed 48 weeks of treatment, 100 in the PEG-IFN group and 100 in the ETV group. During 3-6 months of treatment, compared with baseline, the PEG-IFN group showed a significant decrease in interferon-gamma (IFN-γ), interleukin-17A (IL-17A), interleukin-6(IL-6), interleukin-10(IL-10), and transforming growth factor beta (TGF-β) ( < 0.001) and a significant increase in interferon-alpha 2(IFN-α2) ( < 0.001). In the ETV group, IL-10 and TGF-β1 decreased significantly ( < 0.001). After 3 months, the levels of IFN-α2, IL-17A, and tumor necrosis factor-alpha(TNF-α) in the PEG-IFN group were significantly higher than those in the ETV group ( < 0.01). The levels of IL-6 and TGF-β3 were significantly lower than those in the ETV group ( < 0.01). After 6 months, the levels of IFN-α2, IFN-γ, and TNF-α in the PEG-IFN group were significantly higher than those in the ETV group ( < 0.01), while the levels of IL-6 and TGF-β3 were significantly lower than those in the ETV group ( < 0.01). Compared with ETV, PEG-IFN had higher HBeAg and HBsAg disappearance rates.
During antiviral therapy, a change in the cytokine profile occurred; in the aspect of immune control and functional cure, PEG-IFN was significantly better than ETV.
研究慢性乙型肝炎（CHB）患者抗病毒治疗后细胞因子谱的变化。
采用聚乙二醇干扰素（PEG-IFN）和恩替卡韦（ETV）治疗 HBeAg 阳性患者。在基线和每 3 个月检测临床生化和细胞因子。
共有 200 例患者完成了 48 周的治疗，PEG-IFN 组 100 例，ETV 组 100 例。在治疗 3-6 个月时，与基线相比，PEG-IFN 组干扰素-γ（IFN-γ）、白细胞介素-17A（IL-17A）、白细胞介素-6（IL-6）、白细胞介素-10（IL-10）和转化生长因子-β（TGF-β）显著降低（ < 0.001），干扰素-α2（IFN-α2）显著升高（ < 0.001）。在 ETV 组中，IL-10 和 TGF-β1 显著降低（ < 0.001）。治疗 3 个月后，PEG-IFN 组 IFN-α2、IL-17A 和肿瘤坏死因子-α（TNF-α）水平明显高于 ETV 组（ < 0.01）。IL-6 和 TGF-β3 水平明显低于 ETV 组（ < 0.01）。治疗 6 个月后，PEG-IFN 组 IFN-α2、IFN-γ 和 TNF-α水平明显高于 ETV 组（ < 0.01），而 IL-6 和 TGF-β3 水平明显低于 ETV 组（ < 0.01）。与 ETV 相比，PEG-IFN 具有更高的 HBeAg 和 HBsAg 清除率。
抗病毒治疗过程中细胞因子谱发生变化；在免疫控制和功能治愈方面，PEG-IFN 明显优于 ETV。
